Fig. 2: In vivo protective efficacy of DA03E17. | Nature Communications

Fig. 2: In vivo protective efficacy of DA03E17.

From: A broadly protective human monoclonal antibody targeting the sialidase activity of influenza A and B virus neuraminidases

Fig. 2

A Four mice per group were intraperitoneally inoculated with DA03E17 (red line), 1G01 (blue line), or the negative control mAb (gray line) at 10 mg/kg; 1430E3/9 and F3A19 were used as negative controls for IAVs and an IBV, respectively. One day later, the mice were challenged with 10 MLD50 of the indicated challenge viruses. Body weight changes and survival were monitored daily for 14 days. Body weight changes are shown as the mean ± SDs. B Four mice per group were intraperitoneally injected with the indicated antibodies at 10 mg/kg. One day later, the mice were challenged with 10 MLD50 of the A/H1N1pdm09 virus. On days 2 and 4 post-infection, virus titers in the lungs were determined. Source data are provided as a Source Data file. *P < 0.01 (one-way ANOVA followed by Dunnett’s tests).

Back to article page